Vaccine’, a reputed peer-reviewed international journal, Publishes Phase-III Results of PNEUBEVAX 14TM BE-PCV-14 can be given safely to infants to prevent Pneumococcal Disease PNEUBEVAX 14TM induced robust & functional serotype specific immune response in infants to 14 serotypes offering broadest serotype coverage of any
IVI will complete the technology transfer by 2025 Oral Cholera Vaccine to be manufactured by Biological E. Limited for India and international markets SEOUL, Republic of Korea and HYDERABAD, India — The International Vaccine Institute (IVI), an international organization with a mission to discover,
Biological E. Limited (BE) to Manufacture Up to 50 Million Doses of QDENGA Per Year, Accelerating Takeda’s Ability to Deliver 100 Million Doses Per Year by 2030 At the Latest Addresses the Specific Need to Offer Multi-Dose Vials for National Immunization Programs to
Currently around 300 million doses of ready-to-use CORBEVAXTM doses Biological E. Limited’s production capacity is up to 1 billion vaccines annually On the occasion of National Immunisation Day today and in an effort to support the Government’s ongoing efforts to protect our country against
From Microsoft & Medtronic to WHO and Johnson & Johnson, Asia’s biggest biotechnology conference announces a diverse range of experts from technology and healthcare industries Conference to host about 50 speakers, participating across in 7 panels, 2 keynote addresses, a CEO Conclave and a
